SG Americas Securities LLC Buys 37,823 Shares of Adaptive Biotechnologies Corporation $ADPT

SG Americas Securities LLC grew its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 37.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 137,758 shares of the company’s stock after buying an additional 37,823 shares during the quarter. SG Americas Securities LLC owned 0.09% of Adaptive Biotechnologies worth $1,912,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ADPT. AQR Capital Management LLC raised its holdings in shares of Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies in the 1st quarter worth $93,000. New York State Common Retirement Fund increased its holdings in Adaptive Biotechnologies by 39.2% during the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Adaptive Biotechnologies by 728.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock worth $4,417,000 after purchasing an additional 333,379 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Insider Activity at Adaptive Biotechnologies

In other news, CFO Kyle Piskel sold 3,115 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $13.04, for a total value of $40,619.60. Following the completion of the sale, the chief financial officer owned 256,725 shares of the company’s stock, valued at approximately $3,347,694. This represents a 1.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Francis Lo sold 39,741 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the completion of the transaction, the insider directly owned 250,934 shares of the company’s stock, valued at $4,388,835.66. This represents a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 698,316 shares of company stock worth $11,655,488. Insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JPMorgan Chase & Co. cut their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. TD Cowen boosted their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Guggenheim upped their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.50.

Adaptive Biotechnologies Trading Down 5.3%

Shares of ADPT stock opened at $21.19 on Friday. The firm’s fifty day moving average price is $15.95 and its two-hundred day moving average price is $15.83. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $22.80. The firm has a market capitalization of $3.39 billion, a P/E ratio of -64.21 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.20) EPS. As a group, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.